2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Melanoma
34
Neoplasms
14
Carcinoma, Non-Small-Cell Lung
10
Colorectal Neoplasms
8
Ovarian Neoplasms
7
Multiple Myeloma
6
Breast Neoplasms
6
Pancreatic Neoplasms
5
Neoplasm Metastasis
4
Hematologic Neoplasms
4
Solid Tumors
3
Neoplasms by Site
3
Lymphoma, Non-Hodgkin
3
Lung Neoplasms
3
Leukemia, Myeloid, Acute
3
Gastrointestinal Neoplasms
3
Cholangiocarcinoma
3
Brain Neoplasms
3
Urinary Bladder Neoplasms
2
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Thyroid Cancer, Papillary
2
Solid Tumor
2
Skin Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Neoplasms by Histologic Type
2
Leukemia, Myelomonocytic, Chronic
2
Gallbladder Neoplasms
2
Fallopian Tube Neoplasms
2
Interventions
relatlimab
1
daratumumab
1
cobimetinib
1
Nivolumab
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Microsatellite Unstable Colorectal Cancer
×
cobimetinib
×
Clear all
NCT02060188
2025-11-06
CheckMate142
Bristol-Myers Squibb
Phase 2
Completed
385 enrolled
17 charts
2 FDA